New indication for alpha-msh analogues
OwnerPhilippe WOLGENinventor
Life of this patent
Estimating the term…
Abstract
The present invention is directed to alpha-MSH analogues for treatment of neurodegenerative disorders.
Claims15
Alpha-MSH analogue for use in treatment of a human subject with a neurodegenerative disorder wherein the interval between subsequent administrations of the alpha-MSH analogue is between at least 6 weeks and at most 8 weeks.
Method of treating neurodegenerative disorders by administering an alpha-MSH analogue to a human subject suffering from neurodegenerative disorder, wherein the interval between subsequent administrations of the alpha-MSH analogue is at least 6 weeks and at most 8 weeks.
Use of an alpha-MSH analogue for the manufacture of a medicament for the treatment of a human subject with a neurodegenerative disorder wherein the interval between subsequent administrations of the alpha-MSH analogue is at least 6 weeks and at most 8 weeks.
Dependencies are inferred from the claim text.